Sava Infond D.O.O. Biogen Inc. Call Options Transaction History
Sava Infond D.O.O.
- $566 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BIIB
# of Institutions
996Shares Held
128MCall Options Held
1.28MPut Options Held
1.49M-
Vanguard Group Inc Valley Forge, PA16.7MShares$2.23 Billion0.05% of portfolio
-
Primecap Management CO Pasadena, CA16MShares$2.14 Billion1.94% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$1.94 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.34MShares$980 Million0.06% of portfolio
-
Wellington Management Group LLP Boston, MA4.93MShares$658 Million0.14% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $19.2B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...